Syros Pharmaceuticals (SYRS) Expected to Announce Quarterly Sales of $1.33 Million

Wall Street brokerages expect that Syros Pharmaceuticals (NASDAQ:SYRS) will post sales of $1.33 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Syros Pharmaceuticals’ earnings, with estimates ranging from $370,000.00 to $3.21 million. The company is expected to announce its next earnings results on Wednesday, August 8th.

On average, analysts expect that Syros Pharmaceuticals will report full-year sales of $3.34 million for the current financial year, with estimates ranging from $370,000.00 to $10.00 million. For the next year, analysts anticipate that the company will report sales of $1.53 million per share, with estimates ranging from $600,000.00 to $2.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, May 10th. The company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.14). The firm had revenue of $0.37 million for the quarter, compared to analyst estimates of $3.41 million.



SYRS has been the topic of several research analyst reports. HC Wainwright reissued a “hold” rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday, March 14th. BidaskClub cut shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, April 6th. Wedbush reaffirmed an “outperform” rating and issued a $13.00 price objective (up from $11.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, March 13th. ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 6th. Finally, Zacks Investment Research cut shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 16th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $21.13.

Shares of SYRS traded down $0.30 during mid-day trading on Friday, hitting $12.78. 2,023 shares of the company traded hands, compared to its average volume of 245,097. Syros Pharmaceuticals has a one year low of $6.30 and a one year high of $24.38. The stock has a market capitalization of $435.57 million, a P/E ratio of -6.14 and a beta of -2.69.

Several hedge funds and other institutional investors have recently made changes to their positions in SYRS. Two Sigma Advisers LP bought a new position in shares of Syros Pharmaceuticals during the fourth quarter worth $105,000. Adalta Capital Management LLC bought a new position in shares of Syros Pharmaceuticals during the fourth quarter worth $111,000. The Manufacturers Life Insurance Company boosted its position in shares of Syros Pharmaceuticals by 299.9% during the first quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock worth $168,000 after purchasing an additional 9,691 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Syros Pharmaceuticals during the fourth quarter worth $191,000. Finally, Two Sigma Investments LP boosted its position in shares of Syros Pharmaceuticals by 80.3% during the fourth quarter. Two Sigma Investments LP now owns 21,197 shares of the company’s stock worth $206,000 after purchasing an additional 9,439 shares in the last quarter. 56.84% of the stock is currently owned by institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply